# Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

> **NCT00457067** · PHASE1 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 5 (—)

## Conditions studied

- Telangiectasia

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00457067
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-27
- **Primary completion:** —
- **Final completion:** 2007-10-24
- **Target enrollment:** 5 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457067, "Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00457067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*